Quantcast

Latest Zoledronic acid Stories

2014-03-24 23:00:59

Understanding bone health is critical for advanced stage prostate cancer patients. Malecare Cancer Support is presenting a free teleconference for prostate cancer patients and their families with noted urologist Neil Shore, MD. New York, NY (PRWEB) March 24, 2014 Malecare Prostate Cancer Support will present a teleconference titled, "Bone Health and Prostate Cancer.” The conference is scheduled for Tuesday, March 25, 2014 at 6PM ET. The teleconference is available without cost and...

2013-12-03 11:15:50

Findings to help physicians guide treatment options for women A study comparing the efficacy and tolerability of two popular osteoporosis drugs, denosumab and zoledronic acid, found that denosumab had a significantly greater effect on increasing spine bone mineral density and zoledronic acid caused more flulike symptoms. These findings were presented recently at the American Society for Bone and Mineral Research’s annual meeting. Researchers performed a retrospective chart review and...

2013-11-11 23:00:44

ChinaMarketResearchReports.com adds Latest Report on “Research Report on China Osteoporosis Drug Market, 2013-2017” to its store. Dallas, TX (PRWEB) November 12, 2013 Osteoporosis is a systemic bone disease, a common disease among middle and old-aged people. It is characterized by low bone mineral density and deterioration of bone microarchitecture, which can lead to increased risks of fragility fracture. There are over 200 million osteoporosis patients around the world in the current...

2013-09-12 23:18:41

Transparency Market Research published new "Global Osteoporosis Drug Market- China Industry Analysis, Size, Share, Growth, Trends and Forecast, 2010 - 2015" market research report to its report store. Browse the report with TOC; visit http://www.transparencymarketresearch.com/osteoporosis-drug-market.html. Albany, New York (PRWEB) September 12, 2013 According to Transparency Market Research “Osteoporosis Drug Market- Global and China market analysis, size, trends and forecast...

2013-04-17 17:27:26

Study results suggest combination treatments may be needed to stop bone loss, fuel growth Although the drug zoledronic acid slows bone loss in osteoporosis patients, it also boosts levels of a biomarker that stops bone formation, according to a recent study accepted for publication in The Endocrine Society's Journal of Clinical Endocrinology & Metabolism (JCEM). Osteoporosis weakens bones and increases the risk patients will suffer fractures. The findings suggest combination therapy...

2013-03-19 15:02:19

The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today. "There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic...

2012-07-16 23:02:52

Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral bisphosphonate. According to the FDA, bisphosphonates may not provide any long-term benefits while simultaneously increasing the risk of atypical femur fractures. New York, New York (PRWEB) July 16, 2012 Parker Waichman LLP has filed a lawsuit on behalf of an Indiana woman who suffered a left and right femur fracture after taking Fosamax, an oral...


Word of the Day
jument
  • A beast of burden; also, a beast in general.
'Jument' ultimately comes from the Latin 'jugum,' yoke.
Related